{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:53:16Z","timestamp":1791471196673,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obstetrics and Gynecology Clinics of North America"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ogc.2026.03.008","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:29:12Z","timestamp":1778815752000},"page":"423-434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neurokinin 3 Receptor Antagonists for Menopause Symptom Management"],"prefix":"10.1016","volume":"53","author":[{"given":"Laura L.","family":"Faubion","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline P.","family":"Tatit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrisandra","family":"Shufelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie S.","family":"Faubion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ogc.2026.03.008_bib1","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.2105\/AJPH.2005.066936","article-title":"Longitudinal analysis of the association between vasomotor symptoms and race\/ethnicity across the menopausal transition: study of women\u2019s health across the nation","volume":"96","author":"Gold","year":"2006","journal-title":"Am J Public Health"},{"issue":"2","key":"10.1016\/j.ogc.2026.03.008_bib2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.maturitas.2008.12.006","article-title":"Menopause-specific questionnaire assessment in US population-based study shows negative impact on health-related quality of life","volume":"62","author":"Williams","year":"2009","journal-title":"Maturitas"},{"issue":"5","key":"10.1016\/j.ogc.2026.03.008_bib3","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/GME.0b013e31827d38a5","article-title":"Impact of the severity of vasomotor symptoms on health status, resource use, and productivity","volume":"20","author":"Whiteley","year":"2013","journal-title":"Menopause"},{"issue":"6","key":"10.1016\/j.ogc.2026.03.008_bib4","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.mayocp.2023.02.025","article-title":"Impact of menopause symptoms on women in the workplace","volume":"98","author":"Faubion","year":"2023","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"10.1016\/j.ogc.2026.03.008_bib5","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of the North American menopause society","volume":"29","year":"2022","journal-title":"Menopause"},{"issue":"12","key":"10.1016\/j.ogc.2026.03.008_bib6","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/GME.0000000000002265","article-title":"Prevalence and impact of vasomotor symptoms due to menopause among women in Brazil, Canada, Mexico, and Nordic Europe: a cross-sectional survey","volume":"30","author":"Todorova","year":"2023","journal-title":"Menopause"},{"issue":"6","key":"10.1016\/j.ogc.2026.03.008_bib7","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/GME.0000000000002200","article-title":"The 2023 nonhormone therapy position statement of the North American Menopause Society","volume":"30","year":"2023","journal-title":"Menopause"},{"issue":"10382","key":"10.1016\/j.ogc.2026.03.008_bib8","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0140-6736(23)00085-5","article-title":"Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study","volume":"401","author":"Lederman","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ogc.2026.03.008_bib9","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamainternmed.2025.4421","article-title":"Elinzanetant for the treatment of vasomotor symptoms associated with menopause: a phase 3 randomized clinical trial","volume":"185","author":"Panay","year":"2025","journal-title":"JAMA Intern Med"},{"issue":"16","key":"10.1016\/j.ogc.2026.03.008_bib10","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/jama.2024.14618","article-title":"Elinzanetant for the treatment of vasomotor symptoms associated with menopause: OASIS 1 and 2 randomized clinical trials","volume":"332","author":"Pinkerton","year":"2024","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ogc.2026.03.008_bib11","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/brain\/89.3.589","article-title":"The subventricular nucleus of the human hypothalamus","volume":"89","author":"Sheehan","year":"1966","journal-title":"Brain"},{"key":"10.1016\/j.ogc.2026.03.008_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2023.1254287","article-title":"Neural substrates underlying rhythmic coupling of female reproductive and thermoregulatory circuits","volume":"14","author":"Grant","year":"2023","journal-title":"Front Physiol"},{"issue":"4408","key":"10.1016\/j.ogc.2026.03.008_bib13","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.462193","article-title":"Menopausal flushes: a neuroendocrine link with pulsatile luteninizing hormone secreation","volume":"205","author":"Casper","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.ogc.2026.03.008_bib14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0079-6123(08)64574-4","article-title":"Hormonal influences on morphology and neuropeptide gene expression in the infundibular nucleus of postmenopausal women","volume":"93","author":"Rance","year":"1992","journal-title":"Prog Brain Res"},{"issue":"6","key":"10.1016\/j.ogc.2026.03.008_bib15","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1210\/er.2009-0005","article-title":"Kisspeptin signaling in the brain","volume":"30","author":"Oakley","year":"2009","journal-title":"Endocr Rev"},{"issue":"7","key":"10.1016\/j.ogc.2026.03.008_bib16","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1210\/jc.2007-0553","article-title":"Hypertrophy and increased kisspeptin gene expression in the hypothalamic infundibular nucleus of postmenopausal women and ovariectomized monkeys","volume":"92","author":"Rometo","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ogc.2026.03.008_bib17","first-page":"2111","article-title":"The effects of hormone replacement therapy on hypothalamic neuropeptide gene expression in a primate model of menopause","volume":"84","author":"Abel","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ogc.2026.03.008_bib18","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/cne.21086","article-title":"Coexpression of dynorphin and neurokinin B immunoreactivity in the rat hypothalamus: morphologic evidence of interrelated function within the arcuate nucleus","volume":"498","author":"Burke","year":"2006","journal-title":"J Comp Neurol"},{"issue":"2","key":"10.1016\/j.ogc.2026.03.008_bib19","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1210\/en.2003-0894","article-title":"Estrogen regulation of neurokinin B gene expression in the mouse arcuate nucleus is mediated by estrogen receptor alpha","volume":"145","author":"Dellovade","year":"2004","journal-title":"Endocrinology"},{"issue":"8","key":"10.1016\/j.ogc.2026.03.008_bib20","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2826.2003.01054.x","article-title":"Short-term effect of oestradiol on neurokinin B mRNA expression in the infundibular nucleus of ewes","volume":"15","author":"Pillon","year":"2003","journal-title":"J Neuroendocrinol"},{"issue":"4","key":"10.1016\/j.ogc.2026.03.008_bib21","first-page":"337","article-title":"Neurokinin B gene expression is increased in the arcuate nucleus of ovariectomized rats","volume":"60","author":"Rance","year":"1994","journal-title":"Neuroendocrinology"},{"issue":"2","key":"10.1016\/j.ogc.2026.03.008_bib22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.brainres.2004.08.026","article-title":"Central injection of senktide, an NK3 receptor agonist, or neuropeptide Y inhibits LH secretion and induces different patterns of Fos expression in the rat hypothalamus","volume":"1026","author":"Sandoval-Guzman","year":"2004","journal-title":"Brain Res"},{"issue":"9","key":"10.1016\/j.ogc.2026.03.008_bib23","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1210\/en.2005-0488","article-title":"Regulation of Kiss1 gene expression in the brain of the female mouse","volume":"146","author":"Smith","year":"2005","journal-title":"Endocrinology"},{"issue":"11","key":"10.1016\/j.ogc.2026.03.008_bib24","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1210\/en.2013-1331","article-title":"Kisspeptin, neurokinin B, and dynorphin act in the arcuate nucleus to control activity of the GnRH pulse generator in ewes","volume":"154","author":"Goodman","year":"2013","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.ogc.2026.03.008_bib25","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.yfrne.2013.07.003","article-title":"Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes","volume":"34","author":"Rance","year":"2013","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.ogc.2026.03.008_bib26","doi-asserted-by":"crossref","first-page":"8466","DOI":"10.1038\/srep08466","article-title":"Neurokinin B administration induces hot flushes in women","volume":"5","author":"Jayasena","year":"2015","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.ogc.2026.03.008_bib27","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3109\/00365528609015169","article-title":"Flushing and plasma substance P concentration during infusion of synthetic substance P in normal man","volume":"21","author":"Schaffalitzky De Muckadell","year":"1986","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"10.1016\/j.ogc.2026.03.008_bib28","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/GME.0000000000000763","article-title":"Association of genetic variation in the tachykinin receptor 3 locus with hot flashes and night sweats in the Women\u2019s Health Initiative Study","volume":"24","author":"Crandall","year":"2017","journal-title":"Menopause"},{"issue":"2","key":"10.1016\/j.ogc.2026.03.008_bib29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.celrep.2018.06.037","article-title":"A neural circuit underlying the generation of hot flushes","volume":"24","author":"Padilla","year":"2018","journal-title":"Cell Rep"},{"issue":"11","key":"10.1016\/j.ogc.2026.03.008_bib30","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1210\/en.2015-1409","article-title":"The NK3 receptor antagonist ESN364 interrupts pulsatile LH secretion and moderates levels of ovarian hormones throughout the menstrual cycle","volume":"156","author":"Fraser","year":"2015","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.ogc.2026.03.008_bib31","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1210\/jc.2015-3621","article-title":"The NK3 receptor antagonist ESN364 suppresses sex hormones in men and women","volume":"101","author":"Fraser","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.ogc.2026.03.008_bib32","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1210\/jc.2019-00677","article-title":"Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial","volume":"104","author":"Depypere","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ogc.2026.03.008_bib33","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/GME.0000000000001510","article-title":"A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause","volume":"27","author":"Fraser","year":"2020","journal-title":"Menopause"},{"issue":"10081","key":"10.1016\/j.ogc.2026.03.008_bib34","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(17)30823-1","article-title":"Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"389","author":"Prague","year":"2017","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.ogc.2026.03.008_bib35","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000033978","article-title":"Neurokinin 1\/3 receptor antagonists for menopausal women: a current systematic review and insights into the investigational non-hormonal therapy","volume":"102","author":"Hassan","year":"2023","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.ogc.2026.03.008_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174207","article-title":"Effects of neurokinin 3 receptor antagonist fezolinetant on hot flash-like symptoms in ovariectomized rats","volume":"905","author":"Tahara","year":"2021","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10.1016\/j.ogc.2026.03.008_bib37","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/GME.0000000000001500","article-title":"Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial","volume":"27","author":"Trower","year":"2020","journal-title":"Menopause"},{"issue":"3","key":"10.1016\/j.ogc.2026.03.008_bib38","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/GME.0000000000002138","article-title":"Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1)","volume":"30","author":"Simon","year":"2023","journal-title":"Menopause"},{"issue":"8","key":"10.1016\/j.ogc.2026.03.008_bib39","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1210\/clinem\/dgad058","article-title":"Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: a phase 3 RCT","volume":"108","author":"Johnson","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ogc.2026.03.008_bib40","doi-asserted-by":"crossref","first-page":"39S","DOI":"10.1097\/01.AOG.0000825808.38519.3b","article-title":"Phase 3 study of fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause [A132]","volume":"139","author":"Lederman","year":"2022","journal-title":"Obstet Gynecol"},{"issue":"12","key":"10.1016\/j.ogc.2026.03.008_bib41","doi-asserted-by":"crossref","first-page":"6905","DOI":"10.1097\/MS9.0000000000001659","article-title":"Revolutionary treatment for menopausal symptoms: veozah (Fezolinetant) receives FDA approval","volume":"86","author":"Mughal","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"issue":"4","key":"10.1016\/j.ogc.2026.03.008_bib43","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/AOG.0000000000005114","article-title":"Safety of fezolinetant for vasomotor symptoms associated with menopause: a randomized controlled trial","volume":"141","author":"Neal-Perry","year":"2023","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ogc.2026.03.008_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-079525","article-title":"Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial","volume":"387","author":"Schaudig","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.ogc.2026.03.008_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.maturitas.2024.108159","article-title":"Effect of fezolinetant on patient-reported quality-of-life outcomes: data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy","volume":"193","author":"Shapiro","year":"2025","journal-title":"Maturitas"},{"issue":"Pt 3","key":"10.1016\/j.ogc.2026.03.008_bib46","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1113\/jphysiol.2006.112508","article-title":"Neurokinin-1 receptor desensitization attenuates cutaneous active vasodilatation in humans","volume":"577","author":"Wong","year":"2006","journal-title":"J Physiol"},{"issue":"12","key":"10.1016\/j.ogc.2026.03.008_bib47","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.5665\/sleep.3208","article-title":"Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia","volume":"36","author":"Ratti","year":"2013","journal-title":"Sleep"},{"issue":"6","key":"10.1016\/j.ogc.2026.03.008_bib48","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/GME.0000000000002350","article-title":"Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause","volume":"31","author":"Pinkerton","year":"2024","journal-title":"Menopause"},{"issue":"6","key":"10.1016\/j.ogc.2026.03.008_bib49","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s40271-025-00748-4","article-title":"Exit interviews examining changes to mood and Work\/productivity impacts related to vasomotor symptoms: perspectives of postmenopausal women receiving elinzanetant in phase III clinical trials","volume":"18","author":"Haberland","year":"2025","journal-title":"Patient"},{"issue":"1","key":"10.1016\/j.ogc.2026.03.008_bib51","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40265-025-02244-3","article-title":"Elinzanetant: first approval","volume":"86","author":"Lee","year":"2026","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.ogc.2026.03.008_bib52","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70282","article-title":"The effects of elinzanetant on simulated driving performance in healthy women: a randomized phase I study","volume":"18","author":"Francke","year":"2025","journal-title":"Clin Transl Sci"},{"issue":"8","key":"10.1016\/j.ogc.2026.03.008_bib53","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa2415566","article-title":"Elinzanetant for vasomotor symptoms from endocrine therapy for breast cancer","volume":"393","author":"Cardoso","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ogc.2026.03.008_bib54","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1210\/en.2010-1345","article-title":"Substance P (SP)-neurokinin-1 receptor (NK-1R) alters adipose tissue responses to high-fat diet and insulin action","volume":"152","author":"Karagiannides","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.ogc.2026.03.008_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121078","article-title":"Neurokinin 3 receptor antagonist-induced adipocyte activation improves obesity and metabolism in PCOS-like mice","volume":"310","author":"Zhang","year":"2022","journal-title":"Life Sci"},{"issue":"11","key":"10.1016\/j.ogc.2026.03.008_bib56","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1210\/jc.2016-1202","article-title":"Neurokinin B receptor antagonism in women with polycystic ovary syndrome: a randomized, placebo-controlled trial","volume":"101","author":"George","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.ogc.2026.03.008_bib57","doi-asserted-by":"crossref","first-page":"e3519","DOI":"10.1210\/clinem\/dgab320","article-title":"Randomized controlled trial of neurokinin 3 receptor antagonist fezolinetant for treatment of polycystic ovary syndrome","volume":"106","author":"Fraser","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ogc.2026.03.008_bib58","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf002","article-title":"Management of vasomotor symptoms in cancer patients","volume":"30","author":"Zhu","year":"2025","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ogc.2026.03.008_bib59","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1056\/NEJMc2412361","article-title":"Neurokinin-3 receptor antagonism for refractory hot flashes in men","volume":"392","author":"Lin","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Obstetrics and Gynecology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889854526000197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889854526000197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T19:08:30Z","timestamp":1785179310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889854526000197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0889854526000197"],"URL":"https:\/\/doi.org\/10.1016\/j.ogc.2026.03.008","relation":{},"ISSN":["0889-8545"],"issn-type":[{"value":"0889-8545","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurokinin 3 Receptor Antagonists for Menopause Symptom Management","name":"articletitle","label":"Article Title"},{"value":"Obstetrics and Gynecology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ogc.2026.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}